UniQure Completes Strategic Review To Refocus Its Pipeline, Reduce Operating Costs And Deliver Long-Term Shareholder Value

~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington, MA

~ Preparation Underway for Late-Stage Development in Hemophilia B

~ Cost Savings Expected to Extend Cash Resources into 2019

~ Company to Host Investor Conference Call Today at 8:30 a.m. ET

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the completion of a company-wide strategic review aimed at refocusing its pipeline, consolidating its manufacturing and enhancing overall execution to drive shareholder value.  As a result of this initiative, the Company will prioritize programs in hemophilia B, Huntington's disease and those associated with its landmark collaboration with Bristol-Myers Squib (BMS) in cardiovascular disease.  Additionally, the Company will restructure its research and development organization in the Netherlands and consolidate manufacturing in the United States. These actions are expected to reduce operating expenses and create a more efficient company focused on the successful and timely development of gene therapies for patients with serious unmet medical needs.

As part of its effort to focus resources on key priorities, uniQure has initiated discussions with its collaborator regarding the potential discontinuation of licensing discussions for AMT-110 for the treatment of Sanfilippo B, and will pursue partnering opportunities for its academic-sponsored program in Parkinson's disease.

uniQure expects to realize €5 to €6 million of annualized cost savings in personnel and other related operating expenses as a result of the elimination of approximately 50 to 60 positions, or 20% to 25% of global headcount, by the end of 2017. Additionally, the Company expects to further reduce planned operating expenses by €11 to €15 million over the next two years through the focusing of its pipeline. Based on its strong cash position and the above actions, uniQure believes its existing cash resources will be sufficient to fund operations into 2019.

If you liked this article you might like

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

5 Stocks Setting Up for Big Breakouts

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

8 Stocks Under $10 to Trade for Huge Profits